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(HCV) NS3/4A protease inhibitor approved for treatment of
chronic HCV infection. Baseline NS3 polymorphisms in all
patients and emerging mutations in patients who failed to
achieve sustained virologic response (SVR) with simeprevir plus
peginterferon/ribavirin (PR) in Phase IIb/III studies are described.
Methods: Baseline sequencing data were available for 2007
genotype 1 (GT1)-infected patients. Post-baseline data were
available for 197/245 simeprevir-treated patients who did not
achieve SVR. In vitro simeprevir susceptibility was assessed in a
transient replicon assay as site-directed mutants or in chimeric
replicons with patient-derived NS3 protease sequences.
Results: Baseline NS3 polymorphisms at positions associated
with reduced in vitro susceptibility to simeprevir (43, 80, 122,
155, 156, and/or 168; EC50 fold change >2.0) were uncommon
(1.3% [26/2007]), with the exception of Q80K, which confers
10-fold reduction in simeprevir activity in vitro (13.7%
[274/2007]; GT1a 29.5% [269/911], GT1b 0.5% [5/1096]).
Baseline Q80K had minor effect on initial response to
simeprevir/PR, but resulted in lower SVR rates. Overall, 91.4% of
simeprevir-treated patients [180/197] without SVR had emerging
mutations at NS3 positions 80, 122, 155, and/or 168 at failure
(mainly R155K in GT1a with and without Q80K, and D168V in
GT1b), conferring high-level resistance in vitro (EC50 fold change
>50). Emerging mutations were no longer detectable by popula-
tion sequencing at study end in 50% [90/180] of patients (median
follow-up 28.4 weeks).Journal of Hepatology 20
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Hepatitis C virus (HCV) infection represents a major public health
concern, with approximately 150 million individuals infected
worldwide and 3–4 million new infections annually [1]. HCV
infection is the leading cause of liver cirrhosis, hepatocellular
carcinoma, and liver transplantation.
Simeprevir (TMC435) is a recently approved, one-pill,
once-daily (QD), oral HCV NS3/4A protease inhibitor. The
anti-HCV activity of simeprevir plus peginterferon/ribavirin (PR)
in patients with chronic HCV genotype 1 (GT1) infection has been
demonstrated in ﬁve multicenter, Phase IIb/III studies [2–6]. In
Phase IIb studies (PILLAR and ASPIRE), sustained virologic respon-
se (SVR) rates in patients treated with simeprevir/PR were
81–86% in treatment-naïve patients [2], 77–89% in prior relapsers,
and 41–86% in prior null and partial responders [3]. In Phase III
studies (QUEST-1, QUEST-2, and PROMISE), SVR rates were
signiﬁcantly higher in patients who received simeprevir/PR
compared with PR control (80% vs. 50% in treatment-naïve
patients and 79% vs. 37% in prior relapsers) [4–6]. In these
studies, approximately 90% of patients met response-guided
treatment criteria and were eligible for 24 weeks of PR
treatment; SVR rates in these patients ranged from 83% to 91%.
Moreover, simeprevir is generally well tolerated (3800 patients
treated in clinical trials to date).
Treatment failure in HCV-infected patients receiving a
direct-acting antiviral agent (DAA)-based regimen has been asso-
ciated with the emergence of resistance mutations in the target
region of these agents [7,8]. In addition, naturally occurring
amino acid substitutions in NS3 – also referred to as polymor-
phisms – that can reduce the antiviral activity of DAAs have been
reported [9]. In this paper, we describe NS3 baseline polymor-
phisms in HCV GT1-infected patients enrolled in the simeprevir15 vol. 62 j 1008–1014
JOURNAL OF HEPATOLOGY
Phase IIb/III studies. We also describe the effect of baseline NS3
Q80K polymorphism on antiviral activity and efﬁcacy of
simeprevir/PR, and characterize emerging mutations in patients
who received simeprevir/PR and did not achieve SVR.Patients and methods
Study design
NS3 sequence data were analyzed from ﬁve Phase IIb/III studies of simeprevir/PR
(PILLAR, ASPIRE, QUEST-1, QUEST-2, and PROMISE) (Supplementary Table 1)
[2–6]. The prevalence of baseline NS3 polymorphisms was analyzed in all patients
enrolled in these studies (N = 2026 in total; n = 2007 patients with sequence
data). Paired baseline and post-baseline sequences at the time of failure were
available from 197 patients treated with 150 mg simeprevir/PR who did not
achieve SVR. The effect of the NS3 Q80K polymorphism on outcome of treatment
with simeprevir 150 mg QD in combination with PR therapy was assessed by
study and in a pooled analysis of the two Phase III studies in treatment-naïve
patients (QUEST-1 and QUEST-2; n = 515 patients treated with simeprevir/PR
and sequencing data available) [10].
All studies were conducted in full compliance with the Declaration of
Helsinki and Good Clinical Practice guidelines. All patients provided written
informed consent before participating in any study-related activity.HCV NS3/4A sequence analysis and subtype determination
HCV geno/subtypes were determined at screening by Trugene or Versant LiPA
v2 assay (Siemens Healthcare Diagnostics, IL, USA). HCV GT subtypes were
also determined at baseline by sequencing a 329 bp region within NS5B fol-
lowed by basic local alignment search tool (BLAST) analysis. The results of
the NS5B-based assay were used for efﬁcacy and virology analyses.
According to the NS5B-based assay, 15 of the 2026 patients enrolled in the
ﬁve Phase IIb/III studies had non-GT1a/1b subtypes (GT1: n = 4; GT1e:HCV GT1
Phase IIb/III studies
(N = 2007)
Polymorphisms considering NS3
positions 43, 80, 122, 155, 156, and 168
No polymorphism
N = 1429
(71.2%)
Polymorphisms
with SMV FC >2.0
N = 300
(14.9%)
Polymorphisms
with SMV FC ≤2.0
N = 278
(13.9%)
Fig. 1. Prevalence of NS3 polymorphisms in simeprevir Phase IIb/III studies. aFC in EC5
in a transient replicon assay. bIn GT1b backbone. cIn GT1a backbone. EC50, half maximal
simeprevir.
Journal of Hepatology 2015n = 4; GT1d: n = 2; GT1 g, 1i, 1l, 6e, and 6p: each n = 1). Data for patients
with non-GT1a/1b subtypes were analyzed together with that for GT1a
patients.
NS3/4A sequencing was performed at baseline for all patients and
post-baseline for simeprevir/PR-treated patients who did not achieve SVR for
any reason. Samples from patients not achieving SVR were selected for sequenc-
ing based on the timepoint of failure, availability of samples until end of study
(EOS), and the sensitivity of the sequencing assay. The HCV NS3/4A region or
the NS3 protease domain was sequenced using standard Sanger population
sequencing [11].
Polymorphisms were deﬁned as amino acid changes from the H77 (GenBank
accession number AF009606) or the HCV Con1 (GenBank accession number
AJ238799) reference sequences for HCV GT1a/other and GT1b, respectively.
Emerging mutations were deﬁned as amino acid changes from patient-speciﬁc
baseline sequences.
Two lists of NS3 amino acid positions of interest were deﬁned to guide the
analyses. The ﬁrst list comprised six NS3 amino acid positions: 43, 80, 122,
155, 156, and 168; speciﬁc amino acid changes at one or more of these positions
are known to confer reduced susceptibility to simeprevir in vitro [12,13]. The sec-
ond list also included NS3 positions that have been associated with resistance to
other HCV NS3/4A protease inhibitors or that were considered of interest based
on observations in in vitro or in vivo studies with simeprevir [12–15]. This list
comprised 18 NS3 amino acid positions: 36, 41, 43, 54, 55, 80, 107, 122, 132,
138, 155, 156, 158, 168, 169, 170, 174, and 175.
In addition, statistical analyses were performed to identify emerging muta-
tions associated with simeprevir treatment failure (Supplementary Table 2).
Phenotypic characterization using a transient replicon assay
Mutations were engineered in a GT1b or GT1a replicon; for the chimeric replicon
assay, sequences of the NS3 protease domain (aa7-192) derived from patient iso-
lates were introduced into a GT1b replicon backbone generating chimeric repli-
cons. Antiviral activity of simeprevir against the mutants or chimeric replicons
was assessed in a transient replicon assay using luciferase read-out, quantiﬁed
by the half maximal effective concentration (EC50) values, and compared with
that of a reference GT1b wild-type HCV replicon, as described earlier. Fold
changes in EC50 were calculated [12].NS3
polymorphism
SMV FCa Patients
n (%)
Any polymorphism
with SMV FC >2.0
       Q80K
       Q80R
       R155K
       D168E
       Q80K + D168E 
-
7.7b/9.3c
6.9b/13c
33b/88c
43b/26c
373b/589c
300 (14.9)
273 (13.6)
12 (0.6)
6 (0.3)
8 (0.4)
1 (0.05)
NS3
polymorphism
SMV FCb Patients
n (%)
Any polymorphism
with SMV FC ≤2.0
Q80G
Q80L
Q80N
S122C
S122G
S122N
S122T
S122N/T
Q80L + S122G
Q80L + S122N
-
1.7
1.1
0.9
1.1
0.4
1.1
0.5
-
n.a.
n.a.
278 (13.9)
1 (0.05)
39 (1.9)
1 (0.05)
1 (0.05)
111 (5.5)
47 (2.3)
71 (3.5)
3 (0.1)
3 (0.1)
1 (0.05)
 
1.3%
other than Q80K
0 values compared with GT1b wild-type replicon assessed as site-directed mutant
effective concentration; FC, fold change; GT, genotype; n.a., not applicable; SMV,
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Fig. 2. Mean change in HCV RNA levels from baseline by HCV GT subtype and
presence of Q80K in HCV treatment-naïve patients (QUEST-1 and QUEST-2).
BL, baseline; GT, genotype; HCV, hepatitis C virus; PBO, placebo; PR, peginter-
feron/ribavirin; SE, standard error; SMV, simeprevir; w/o, without.
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Results
Baseline NS3 polymorphisms
With the exception of the low-level resistance polymorphism
Q80K, baseline NS3 polymorphisms associated with reduced
in vitro susceptibility to simeprevir (at positions 43, 80, 122,
155, 156, and 168; fold change in EC50 value >2.0 as
site-directed mutant in transient replicon assay) were generally
uncommon (1.3%; 26/2007) (Fig. 1). Among patients treated with
150 mg simeprevir/PR in the Phase IIb/III treatment-naïve and
-experienced studies, 6/9 patients with Q80R, 3/4 with R155K,
and 3/6 with D168E polymorphisms achieved SVR. Given the
low prevalence of these baseline polymorphisms, no conclusion
can be made concerning their possible impact on the outcome
of simeprevir/PR therapy. NS3 polymorphisms at any of the six
positions of interest that did not reduce simeprevir activity in vit-
ro (fold change in EC50 value 62.0) were observed in 13.9% of
patients (Fig. 1). Consistent with the in vitro activity of simeprevir
against these mutants, no impact on treatment outcome was
observed (data not shown). Of note, no polymorphisms were
observed at NS3 amino acid positions 43 and 156.
Overall, the NS3 Q80K polymorphism was present in 13.7% of
patients (274/2007): 29.5% (269/911) of GT1a and 0.5% (5/1096)
of GT1b patients. Large regional differences in Q80K polymor-
phism prevalence were noted with the highest prevalence in
North America (Table 1).
A Q80K amino acid substitution reduced simeprevir activity
in vitro, with a 7.7- and 9.3-fold change in EC50 when tested as
site-directed mutant in GT1b and GT1a replicon backbones,
respectively (Fig. 1). Baseline HCV GT1a isolates carrying Q80K
displayed a median 11-fold change in simeprevir EC50 (n = 33)
(data not shown). Patients with Q80K at baseline experienced a
rapid and pronounced initial decline in HCV RNA from baseline
during treatment with simeprevir/PR in Phase IIb/III studies, con-
sistent with the limited effect of Q80K on simeprevir activity
observed in vitro. In the pooled, treatment-naïve, Phase III studies
(QUEST-1/QUEST-2) [10], treatment with simeprevir/PR resulted
in a mean change in HCV RNA from baseline to week 1 of 4.1
and 4.6 log10 IU/ml in GT1a patients with and without Q80K,
respectively, compared with 1.1 log10 IU/ml in patients treated
with placebo/PR (Fig. 2). However, following the initial decline
in HCV RNA levels, treatment failure occurred more frequently
in simeprevir/PR-treated GT1a patients with baseline Q80K than
in those without this polymorphism. On-treatment failure
occurred in 19.0% (16/84) vs. 7.9% (13/165) of HCV GT1a patients
with and without Q80K, respectively, and viral relapse in 22.2%
(14/63) vs. 6.0% (9/149), respectively. Almost all patients withTable 1. Prevalence of baseline Q80K polymorphism in simeprevir Phase IIb/III
studies.
Region n/N (%)
All HCV GTs HCV GT1aa HCV GT1b
Overall 274/2007 (13.7) 269/911 (29.5) 5/1096 (0.5)
Europe 76/1254 (6.1) 73/377 (19.4) 3/877 (0.3)
North America 185/538 (34.4) 185/385 (48.1) 0/153 (0)
South America 2/60 (3.3) 2/22 (9.1) 0/38 (0)
aIncludes 15 patients with GT non-1a/b.
GT, genotype; HCV, hepatitis C virus.
1010 Journal of Hepatology 2015baseline Q80K who failed simeprevir had emerging mutations
that, in combination with Q80K, conferred high-level resistance
(Table 2).
The SVR rates achieved in HCV GT1a patients with baseline
Q80K were numerically higher in the simeprevir group than in
the placebo/PR group in the pooled QUEST-1/QUEST-2 studies
(58.3% [95% conﬁdence interval {CI} 46.9; 72.4] vs. 52.3% [95%
CI 31.4; 68.1]); however, the difference was not statistically sig-
niﬁcant. Lower SVR rates were observed in the simeprevir group
among HCV GT1a patients with baseline Q80K than in those
without this polymorphism (58.3% [95% CI 46.9; 72.4] vs. 83.6%
[95% CI 82.7; 93.0]). The SVR rate in GT1a patients without
Q80K in the placebo/PR group was 43.4% [95% CI 25.0; 49.5]
([10] and Supplementary Table 3).
Emerging mutations in patients with treatment failure
Of the 1136 treatment-naïve and treatment-experienced patients
(including null and partial responders) treated with
simeprevir/PR in Phase IIb/III studies, 245 did not achieve SVR.
NS3 sequencing data were available for 197 of these 245 patients.
Of these 197 patients, 91.4% (180/197; GT1a: 110/116 [94.8%]
and GT1b: 70/81 [86.4%]) had emerging mutations at NS3 posi-
tions 80, 122, 155, and/or 168 (Table 2).
Although the frequency of emerging mutations in patients
with treatment failure was similar for GT1a and GT1b, different
mutations emerged (Table 2). An emerging mutation at time of
failure was observed in 61/63 GT1a patients (96.8%) without
baseline Q80K. The majority of these patients had emerging
R155K alone (25 patients, 41.0%) or R155K in combination with
other mutations at NS3 positions 80, 122, and/or 168 (22
patients, 36.1%). In 49/53 GT1a patients (92.5%) with baseline
Q80K, an emerging mutation at time of failure was observed.
The majority of these patients (41 patients, 83.7%) had anvol. 62 j 1008–1014
Table 2. Emerging NS3 mutations in patients failing simeprevir/PR treatment (considering NS3 amino acid positions 43, 80, 122, 155, 156, and 168).
GT Patients not achieving SVR 
with emerging mutations at 
time of failure
Emerging mutations at time of failure 
Overview Details
Overall 91.4% (180/197) - -
GT1aa with Q80K 92.5% (49/53) R155K: 83.7% (41/49) 
D168E: 12.2% (6/49) 
Other: 4.1% (2/49) R155K + D168E (n = 1) 
S122R (n = 1)
GT1aa without Q80K 96.8% (61/63) R155K: 41.0% (25/61) 
R155K in combination with 
mutations at positions 80, 122 
and/or 168: 36.1% (22/61)
R155K + D168E (n = 7) 
R155K + D168A, A/V or V (n = 3) 
Q80K or R + R155K (n = 4) 
S122R + R155K (n = 4) 
Q80R or K + R155K + D168E or V (n = 4)
Other: 23.0% (14/61) D168V (n = 6) 
D168A, A/V, E, H (n = 6) 
Q80R + D168E (n = 1) 
S122G + D168A (n = 1)
GT1b 86.4% (70/81) D168V: 60.0% (42/70) 
D168A, E, H, T, A/V or E/V: 
17.1% (12/70)
D168A or A/V (n = 5) 
D168E or E/V (n = 3) 
D168H (n = 2) 
D168T (n = 2)
Other: 22.9% (16/70) Q80R or K + D168E or E/V (n = 9)
Q80R + S122A or T + D168E (n = 2) 
R155Q + D168V (n = 2) 
R155Q + D168A (n = 1) 
S122I or T + D168V or F (n = 2) 
aMay include some patients with GT non-1a/b subtypes.
GT, genotype; PR, peginterferon/ribavirin; SVR, sustained virologic response.
JOURNAL OF HEPATOLOGYemerging R155K mutation at the time of failure, with D168E also
seen (6 patients, 12.2%). In the 70 GT1b patients with emerging
mutations at the time of failure, a mutation at NS3 position 168
emerged alone (D168V in 42 patients [60.0%]; A, A/V, E, E/V, H
or T in 12 patients [17.1%]) or in combination with other muta-
tions at NS3 positions 80, 122, and/or 155 (16 patients [22.9%]).
Of note, emerging R155K was not observed in patients with
GT1b, while some mutations at position 168 were also observed
in patients with GT1a.
Considering the 18 NS3 positions of interest, two additional
patients had emerging mutations (I170T in two GT1a patients
with baseline Q80K). I170T (15-fold change in EC50 values as sin-
gle mutant in GT1a replicon) was also observed in combination
with R155K in three GT1a patients. In addition, in 11 of
197 patients with treatment failure and sequence data available,
mutations at NS3 positions 36 (V36M, n = 1), 107 (V107I, n = 2),
132 (I132L, n = 3), 170 (V170I, n = 1), 174 (S or N174F, or S,
n = 4), and V132L+N174G (n = 1) were observed in combination
with emerging mutations at positions 80, 155, and/or 168. With
the exception of I132L (4.5-fold change in EC50 values), none of
the mutations reduced simeprevir activity (62.0-fold change in
EC50 values) when tested as a single mutant in a GT1b or 1a repli-
con backbone (data not shown). No emerging mutations at the
time of failure were observed at NS3 positions 41, 43, 54, 55,
138, 156, 158, 169, and 175.
Emerging mutations in the NS3 protease domain outside of
the 18 positions of interest were rarely observed (i.e. none in
more than three patients [1.5%] with failure) and almost always
in combination with mutations at positions of interest.Journal of Hepatology 2015Statistical analyses comparing sequence data from
simeprevir/PR-treated patients not achieving SVR against the
respective baseline samples (paired Liddell test) or a reference
sequence set (unpaired Fisher exact test) identiﬁed emerging
mutations Q80R, S122R, R155K, D168A, D168E, D168V, and
V/I170T as being signiﬁcantly associated with simeprevir/PR
treatment failure (Supplementary Table 2).
Of note, although proportions of patients not achieving SVR
differed by prior response to peginterferon treatment, the
proportions of patients with emerging mutations and type of
emerging mutations among the patients failing treatment were
similar irrespective of prior treatment history.
Phenotypic characterization
NS3 sequences derived from clinical isolates obtained at baseline
and time of failure were introduced in a chimeric GT1b replicon,
and susceptibility to simeprevir was assessed. Among the tested
baseline isolates, those carrying a Q80K or R155K amino acid sub-
stitution showed approximately 10- and 90-fold reduction in
simeprevir activity compared with the reference wild-type repli-
con, respectively (Fig. 3). Most of the remaining baseline isolates
tested were fully susceptible to simeprevir in vitro (62.0-fold
change in EC50). Clinical isolates obtained at time of failure gen-
erally showed decreased susceptibility to simeprevir (median
fold change in EC50, 370 [range: 0.2–3110] vs. the reference
wild-type GT1b replicon). All isolates carrying emerging muta-
tions at positions 80, 122, 155, and/or 168 at time of failure
showed an increase in EC50 values vs. their respective baselinevol. 62 j 1008–1014 1011
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Research Articleisolates (median fold change P62 vs. the reference wild-type
GT1b replicon). Of the isolates analyzed, 6 failure isolates did
not carry emerging mutations: one carried an R155K and two a
Q80K amino acid substitution (all GT1a), which were already pre-
sent at baseline. No reduction was observed in susceptibility to
simeprevir between baseline and time of failure, consistent with
the absence of emerging mutations (Fig. 3).
Persistence of emerging mutations
Patients enrolled in the simeprevir Phase IIb/III studies were fol-
lowed for 72 weeks after treatment initiation, irrespective of
treatment duration or outcome. The persistence of viral variants
after treatment failure until the last available timepoint (EOS)
was investigated in simeprevir/PR-treated patients with failure.
Sequences at EOS in patients with treatment failure were
compared against the sequences available at time of failure and
baseline. Median time of the EOS visit after the time of failure
was 28.4 weeks (range: 0–69.9 weeks). For 90/180 patients
(50.0%) with emerging mutations at time of failure, emerging
mutations were no longer observed at EOS with population
sequencing (GT1a: 46/100 [41.8%] and GT1b: 44/70 [62.9%]).
Kaplan-Meier analyses were performed to evaluate the persis-
tence of emerging mutations over time. Median time until the
emerging mutations became undetectable using population
sequencing was shorter in patients infected with HCV GT1b
(24 weeks; range: 19.6–36.1 weeks) compared with GT1a
(36 weeks; range: 31.7–40.9 weeks) (Fig. 4A). Median time until
emerging mutations became undetectable was shorter in patients
with D168V (mainly GT1b [17 weeks; range: 12.1–20.1 weeks])1012 Journal of Hepatology 2015and in GT1a patients with emerging R155K who had baseline
Q80K (32 weeks; range: 30.1–35.9 weeks) compared with GT1a
patients who had emerging R155K without baseline Q80K
(64 weeks; range: 40.1–70.0 weeks) (Fig. 4B).Discussion
Analyses of the HCV NS3/4A sequence at baseline in patients
enrolled in the simeprevir Phase IIb/III studies identiﬁed natural-
ly occurring sequence polymorphisms. However, with the excep-
tion of Q80K, baseline polymorphisms reducing the in vitro
activity of simeprevir were uncommon. Overall, the Q80K poly-
morphism was present in 13.7% of GT1 patients at baseline and
was almost exclusively found with GT1a (29.5%). The prevalence
of Q80K polymorphism within GT1a differs by region. Recent
studies suggest that two clades of GT1a circulate worldwide,
one carrying a lysine (K) with a high prevalence at position 80
and the other carrying a glutamine (Q) [16,17]; for reasons that
are not fully understood, the K80 clade disseminated more effec-
tively in North America than the Q80 clade. In addition, the ratio
of GT1a to GT1b also differs across regions. For example, GT1b isvol. 62 j 1008–1014
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almost exclusively present in the HCV GT1 population of large
parts of Eastern Europe and Asia, while in other regions, such
as North America, GT1a is more prevalent than GT1b. The combi-
nation of the high prevalence of GT1a and the higher prevalence
of Q80K within GT1a resulted in the highest Q80K prevalence in
the GT1 population of North America (34.4%), while the GT1
Q80K prevalence in Europe was 6.1%.
TheQ80K polymorphism is located in the S2 binding site of NS3
and stabilizes the R155 residue, which is relocated during
simeprevir binding to form the extended S2 subsite. Consistent
with these structural features, Q80K as a single mutation in
GT1a backbone reduced the in vitro activity of simeprevir by
9.3-fold, but when Q80K was present in combination with
R155K (88-fold change in EC50 value of R155K alone in GT1a back-
bone), simeprevir activity was reduced by 2000-fold. When
simeprevir was given at lower doses, such as 25 mg or 75 mg,
the presence of a Q80K variant at baseline reduced the decline in
HCV RNA during the ﬁrst few days of treatment, a parameter that
is an indicator of the intrinsic potency of the drug on baseline virus
without the confounding effects of the host factors [2,18]. In con-
trast, in patients receiving simeprevir 150 mg, the initial reduction
in HCV RNA was minimally affected by the presence of Q80K.
The initial antiviral activity in simeprevir/PR-treated HCV
GT1a-infected patients with Q80K at baseline was followed by
higher on-treatment failure and relapse rates, resulting in
lower SVR rates at 12 weeks vs. simeprevir/PR-treated HCV
GT1a-infected patients without this polymorphism. This higher
rate of failure was accompanied by the emergence of additional
mutations (mainly R155K), which in combination with Q80K
resulted in high-level resistance to simeprevir that could not be
contained by the simeprevir drug levels achieved with the
150 mg dose. Based on this observation, it can be speculated that
as a whole, Q80K-containing virus populations might display a
lower resistance barrier, therefore facilitating the emergence of
resistance mutations if the antiviral activity of the PR component
is insufﬁcient to suppress these emerging variants. Of note, SVR
rates with simeprevir/PR regimens in patients with Q80K also
depended on factors associated with response to PR (e.g. IL28B
GT, METAVIR score; Supplementary Table 4). In an
interferon-free regimen of simeprevir combined with sofosbuvir,
high SVR rates at 12 weeks (88%) were achieved in traditionally
difﬁcult-to-cure GT1a-infected patients with Q80K [19].
The majority of patients who failed to respond to
simeprevir/PR treatment had emerging mutations at NS3 posi-
tions 80, 122, 155, and/or 168. These positions are located in,
or close to, the extended S2 binding pocket necessary for
simeprevir binding [12,20]. The mutations present in patients
who failed treatment generally conferred high-level resistance
to simeprevir in vitro, with >50-fold changes in EC50 values com-
pared with the wild-type reference replicon, with the majority of
patients displaying substantially higher levels of resistance.
Additional analyses were performed to assess if mutations
beyond the positions of interest were associated with treatment
failure; the results conﬁrmed that these were either very infre-
quent and/or did not affect the in vitro activity of simeprevir [12].
Emerging mutations differed between patients with GT1a and
GT1b infection, but were consistent within each HCV GT subtype.
In GT1a patients with Q80K, a single emerging R155K mutation
was predominantly observed, while in GT1a patients without
Q80K, double or triple mutations of R155K in combination with
mutations at position 80, 122, and/or 168 were frequentlyJournal of Hepatology 2015present. In GT1b patients, R155K was not observed, and treat-
ment failure was typically associated with emerging mutations
at position 168, mainly D168V. Of note, only one nucleotide
change is needed for an R155K mutation in GT1a, while two
are needed for GT1b [21]. Although emerging mutations at
position 80 and 122 were observed, only some amino acid substi-
tutions at these positions (Q80K, Q80R, and S122R) reduced the
in vitro activity of simeprevir, whereas many other amino acid
substitutions, such as Q80L or S122N, had no effect on simeprevir
activity [12].
Mutations that emerged in patients failing to respond to
simeprevir treatment became undetectable over time in many
patients, based on population sequencing. The follow-up times
in the Phase IIb/III studies were limited and differed substantially
between patients, which could explain the presence of mutations
at the last study-related visit. Kaplan-Meier analyses showed that
the median time until an emerging mutation became unde-
tectable was the shortest for GT1b patients with emerging
D168V. Among GT1a patients, those with Q80K at baseline and
emerging R155K had a shorter time until the emerging R155K
mutation became undetectable, compared with patients with
emerging R155K who did not have Q80K at baseline, suggesting
that emerging variants with R155K in the presence of a Q80K
amino acid substitution are less ﬁt in the absence of simeprevir.
Of note, patients with Q80K polymorphism at baseline who failed
treatment retained this variant throughout the whole study.
Similar results showing that emerging NS3 mutations become
undetectable over time have been described for other DAAs, such
as telaprevir and boceprevir, suggesting lower ﬁtness of these
mutant viral strains [8,22]. Recent studies showed that emerging
mutations that became undetectable by population sequencing
could also not be detected using more sensitive sequencing tech-
nologies [23,24]. However, in the absence of robust re-treatment
data with a protease inhibitor-containing regimen, it is
premature to conclude whether the decline in frequency of the
emerging mutations is clinically relevant. Importantly,
simeprevir resistance mutations remained susceptible to DAAs
with other mechanisms of action in vitro, and recent data with
sofosbuvir/daclatasvir and sofosbuvir/ledipasvir showed success-
ful re-treatment of patients who failed to respond to protease
inhibitor-based treatment with emerging NS3 mutations [25,26].
In conclusion, simeprevir in combination with PR results in
high SVR rates in HCV treatment-naïve and -experienced patients
with HCV GT1 infection. The GT1a NS3 polymorphism Q80K has a
modest impact on simeprevir activity in vitro, but might facilitate
the emergence of additional mutations in patients treated with
simeprevir/PR, especially in those with poor response to interfer-
on, ultimately resulting in lower SVR in these patients when
treated with simeprevir/PR. Treatment failure is typically associ-
ated with emerging high-level resistance mutations in the NS3
region that decline and become undetectable over time in many
patients after treatment is stopped. Recent data suggest that
emerging mutations do not preclude successful treatment out-
come following subsequent treatment with DAAs with other
mechanisms of action.
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